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Abstract
Objective—Endogenous digoxin-like factor (EDLF) has been linked to vasoconstriction, altered
membrane transport and apoptosis. Our objective was to determine whether increased EDLF in the
cord sera of preterm infants was associated with an increased incidence of necrotizing enterocolitis
(NEC).
Methods—Cord sera from pregnant women enrolled in a randomized trial of MgSO4 for fetal
neuroprotection were analyzed for EDLF using a red cell Rb+ uptake assay where inhibition of
sodium pump-mediated Rb+ transport was used as a functional assay of EDLF. Specimens were
assayed blinded to neonatal outcome. Cases (NEC, n=25) and controls (neonates not developing
stage 2 or 3 NEC, n=24) were matched by study center and gestational age. None of the women
had preeclampsia. Cases and controls were compared using the Wilcoxon test for continuous and
the Fisher’s exact test for categorical variables. Conditional logistic regression analysis was used
to assess the odds of case versus control by EDLF level.
Results—Cases and controls were not significantly different for gestational age (GA), race,
maternal steroid use, premature rupture of membranes (PPROM) or MgSO4 treatment. In logistic
models adjusted for treatment group, race, PPROM and GA, cord sera EDLF was significantly
associated with development of NEC (p=0.023).
Conclusions—These data demonstrated an association between cord sera EDLF and NEC.
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INTRODUCTION
Early, preterm deliveries result in infants at risk for major medical complications and death
[1,2]. Among the most serious problems is necrotizing enterocolitis (NEC) which represents
a leading cause of neonatal mortality and morbidity [3,4]. NEC can be characterized by
biochemical and morphologic changes, but the primary cause for this disease is poorly
understood and the immediate mechanisms involved are not fully worked out. The incidence
is inversely related to gestational age and birth weight [1].
NEC is characterized by one or more of the following: reduced bowel motility, bacterial
infection, a marked inflammatory response perhaps representing activation of toll-like
receptor 4, or difficulty in digestion (especially synthetic infant formula) which results in
necrosis of a portion of the intestine [5–7]. It often occurs suddenly and progresses rapidly
and can prove lethal. In severe cases, surgical resection of the bowel is required and this
may result in long term complications, including neurodevelopmental deficits [5,6].
Endogenously produced inhibitors of the sodium pump have been implicated in a number of
diseases, especially hypertensive disorders [8–10]. It is also well documented that the
endogenous digitialis-like factors (EDLFs) are present in the placenta [11–13], in cord
serum [14] and in neonatal blood [14,15]. There is evidence that levels of these factors are
proportionately higher in the neonatal circulation and cord blood the more premature the
delivery [14,15]. The EDLFs by definition block ion transport and consequently nutrient
transport coupled to the sodium pump, but can also cause apoptosis of exposed cells in a cell
type and dose dependent manner [16–18]. Moreover, there is preliminary evidence that
some complications of prematurity are reduced in response to antibody Fab treatment that
targets EDLFs in the maternal circulation just prior to delivery [19]. Thus, we hypothesized
that EDLFs may participate in NEC and that higher EDLF levels are associated with a
higher incidence of NEC.
MATERIALS AND METHODS
Patient Population
Cord sera were obtained as part of a previously completed study, the Beneficial Effects of
Antenatal Magnesium Sulfate (BEAM) Trial carried out under the auspices of the Eunice
Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal
Medicine Units Network. This multicenter trial tested whether prophylactic magnesium
sulfate given to women, for whom preterm delivery was imminent, reduced the risk of death
or moderate to severe cerebral palsy in their children [20]. The study enrolled pregnant
women presenting from 24.0 to 31.6 weeks gestation with advanced preterm labor,
premature rupture of the membranes (pPROM) or indicated deliveries. Women were
randomized to receive either intravenous magnesium sulfate or placebo.
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Cord sera analyzed in this nested case control study were selected by the MFMU Network’s
independent Biostatistics Center at George Washington University to produce a set of
specimens matched for maternal characteristics. Specimens included cord sera from 28
neonate cases with NEC and 27 matched controls (by center and gestational age) selected
for further analysis. Gestational age categories were the following: 24–26 weeks, 27–29
weeks, and 30–32 weeks. Cases were identified as women with a singleton pregnancy
delivering prior to 32 weeks gestation, where the neonate experienced stage 2 or 3 NEC.
Controls were mothers with the same characteristics but where the neonate was live born,
survived to hospital discharge, and experienced no bronchopulminary dysplasia, severe
necrotizing enterocolitis or IVH grades III or IV. Serum volume was sufficient to allow
endogenous digitalis-like factors (EDLFs) levels to be obtained on 25 of the controls and 24
of the cases. Subjects with EDLF values between 0–2% were reassigned a value of zero.
Baseline characteristics are presented in Table 1. None of the selected subjects had
preeclampsia. Researchers analyzing these specimens for EDLF were blinded to case or
control status during the analysis and data evaluation.
Measurement of Endogenous Digitalis-like Factor
A functional assay of EDLF was used. This method has been described in detail [21]. The
approach can be briefly summarized as follows: sodium pump (SP)-dependent Rb+ uptake
into red blood cells from non-pregnant, healthy controls is measured in the presence of
serum from non-pregnant, healthy controls (as a negative, no inhibition control, i.e. maximal
uptake) or in the presence of cord sera from the controls and cases studied. A known
inhibitor of the SP, ouabain, is also added to a fraction of the same cells at a concentration
(10−3M) sufficient to inhibit SP-dependent Rb+ uptake completely (positive control). The
reduction in SP-dependent Rb+ uptake is calculated as a percent of maximal SP dependent
Rb+ uptake. Note Rb+ is not found in detectable levels in cells or the circulation but is an ion
handled equivalently to K+, the natural substrate of the SP, allowing one to monitor uniquely
the rate of the SP mediated Rb+ entry as well as its specific inhibition. Using a RbCl
standard of known concentration (40.4 µg/L), the relative standard deviation (RSD) within
run was 1.46% and run-to-run was 2.67% [21]. The specimens were assayed in duplicate
and the coefficient of variation for duplicates was 5.4%.
Statistical Analysis
Fisher’s Exact test and Wilcoxon’s test were used to compare characteristics between
categorical and continuous variables, respectively. The primary results are presented as
medians with quartiles because of the skewness of the data, although means and standard
errors the mean (SE) are also provided in the text. A conditional logistic regression was used
to assess the odds of case/control status by EDLF level, adjusting for treatment group, race,
PPROM, and stratified by gestational age (categorized as above) at delivery. In evaluating
the two groups 23/25 of the cases and 22/24 of the controls experienced labor and hence
labor status was not assessed in the statistical models. Finally, EDLF values were considered
as a function of the severity of NEC using Spearman correlation analysis. All p-values were
2-sided. A p-value less than 0.05 was considered significant.
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There were no significant differences in maternal characteristics between women having
premature infants who did not develop NEC and those who did (Table 1). All women with
control infants and all the women with infants who developed NEC received steroids. By
design none of the included specimens were obtained from pregnancies complicated by
preeclampsia.
Also, neonatal characteristics were considered for cases and controls (See Table 2). None of
the characteristics was significantly different, however, the length of hospitalization was on
average ∼35 days longer for infants with NEC (p=0.058) as might be predicted.
Association of NEC with cord serum EDLF
The cord levels of ELDF in those infants developing NEC compared with control infants not
developing major neonatal complications were significantly different (control median with
quartiles: 11.95% (0, 25.9) versus cases: 26.2% (16.2, 51.6) EDLF inhibition, p=0.0467;
means + SEM for these data sets are: controls, 16.1 + 3.7 versus cases, 30.7 + 5.3% EDLF
inhibition). See Figure 1. The distribution of these EDLF values for controls and cases is
further described in Table 3. Cord serum EDLF was detectable by the assay in samples of all
cases and in all but 3 of the controls. Cord serum EDLF levels were not statistically different
between controls receiving active Mg2+ treatment compared with controls receiving
placebo. This was also true for NEC positive cases (Data not shown).
Based on a conditional logistic model adjusting for treatment group, race, PPROM, and
stratified by gestational age category at delivery, the EDLF level was significantly
associated with NEC (p=0.0233). For a 10 unit increase in EDLF, the odds of stage 2 or 3
NEC increased by 1.49 (95% CI: 1.06, 2.09). These results were similar to the unadjusted
logistic model (OR for a 10 unit increase in EDLF of 1.46, 95% CI: 1.05, 2.02, p=0.0229).
Additionally, when the severity of NEC was considered, EDLF levels were greater with
more advanced disease, especially stage 3 NEC (p=0.008; See Table 4).
COMMENT
Current understanding of the etiology of NEC is incomplete [3–7]. This study considered an
additional factor in the development of NEC, an endogenous sodium pump inhibitor that has
been implicated in a variety of disease pathways. It may influence both the fetus and later
neonate given its presence in human placenta [11–13], cord sera [14] and neonatal blood
[14,15] with higher levels in premature infants [14,15]. Cord serum levels of EDLFs were
significantly greater in those infants that later developed stage 2 or 3 NEC compared with
infants who did not. While this is only an association, it raises the question of whether
elevated levels of a sodium pump inhibitor could lead to changes in the neonate.
Historically studies have suggested a role for EDLFs in hypertension and renal disease [8].
Indeed, there is evidence that EDLFs may participate in preeclampsia [8–12]. For that
reason we excluded women with preeclampsia from the current study. Additionally, more
recent studies have demonstrated that sodium pump inhibitors can increase pro-
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inflammatory cytokines [22], cause arrest of cell division [18], activate apoptotic pathways
[16–18] and lead to necrosis [23], all features of NEC. Hence, there is biological
plausibility.
In this study, magnesium did not appear to have an effect on EDLF levels given that the
portion of cases and controls receiving active MgSO4 therapy were comparable and direct
comparison of cord EDLF levels in either controls or cases receiving active MgSO4
treatment did not differ respectively from controls or cases receiving placebo. Also,
treatment arm was adjusted for in the multivariate model and there was still a significant
association between EDLF and NEC. In retrospect it would have been interesting to know if
EDLF levels in the mother’s serum paralleled the results found in the cord sera of infants
developing NEC compared with those who did not.
In considering these factors’ possible participation in the development of NEC, it is
recognized that the experiments conducted here do not answer that question directly.
Samples from the infants themselves at the time of their complication were not available for
EDLF analysis. Still, there was an increase in the odds ratio of developing NEC with an
increase in cord serum EDLF level, raising the possibility of some type of interaction
between the two parameters. Similarly, in more advanced NEC, EDLF levels were higher
which is also consistent with a possible interaction between the two parameters.
There has been increased attention to the potential benefit of breast milk and rapid enteral
feeding regimens [24–25], but the time to first feeding and the fraction of infants receiving
breast were not recorded in the original study.
While some known activities of EDLF are found in NEC, the abnormalities observed are not
uniquely produced by EDLFs and could be produced by several pathways. Consequently,
while the results are interesting and potentially represent a contribution of EDLFs to NEC,
additional, more detailed studies, are needed to clarify such questions now that a possible
link has been found.
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Box plot of EDLF level versus clinical status. The cord serum levels of EDLF were plotted
as a function of disease group, showing neonates used as controls (no BPD, NEC or IVH)
and those developing stage 2 or 3 necrotizing enterocolitis (NEC). The “+” symbolizes the
mean.
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  African American 13 (54%) 12 (48%) 1.0
  Hispanic 3 (12.5%) 4 (16%)
  Caucasian 8 (33%) 9 (36%)
Labor type
  Spontaneous 13 (54%) 16 (64%) 0.45
  Induced 7 (29%) 3 (12%)
  No labor 2 (8%) 2 (8%)
  Spontaneous, augmented 2 (8%) 4 (16%)
Pre-eclampsia 0 (0%) 0 (0%) n/a
Any maternal steroid use 24 (100%) 25 (100%) n/a
PPROM 23 (96%) 21 (84%) 0.35
Active treatment group (MgSO4) 11 (46%) 13 (52%) 0.78
Gestational age at delivery (weeks) 28 ± 2 28 ± 2 0.66
Results are presented as means ± SD or N (%)






























Infant weight (g) 1177 ± 295 1200 ± 366 0.75
Female born 11 (46%) 8 (32%) 0.39
Length of stay in NICU (days) 40.9 ± 27.4 75.8 ± 73.3 0.058
Results are presented as means ± SD or N (%)
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Table 4
EDLF Levels as a Function of NEC Severity
Mean EDLF (%) ± SD
No NEC 15.7 ± 17.5 22 controls, no cases
NEC level 1 20.9 ± 29.6 2 controls, no cases
NEC level 2 20.1 ± 22.0 12 cases
NEC level 3 40.5 ± 26.9 13 cases
Trend p=0.008
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